Tags

Type your tag names separated by a space and hit enter

The Effects of Synbiotic Supplementation on Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial.
Probiotics Antimicrob Proteins. 2019 12; 11(4):1355-1361.PA

Abstract

Data on the effects of synbiotic supplementation on glycemic control, lipid profiles, and atherogenic index of plasma (AIP) of women with polycystic ovary syndrome (PCOS) are limited. The purpose of this study was to assess the effects of synbiotic supplementation on glycemic control and lipid profiles in women with PCOS. A prospective, randomized, double-blind, placebo-controlled trial was done at the Naghavi Hospital affiliated to Kashan University of Medical Sciences, Kashan, Iran, between April 2017 and June 2017. Sixty women with PCOS were randomized to intake synbiotic capsule containing Lactobacillus acidophilus strain T16 (IBRC-M10785), Lactobacillus casei strain T2 (IBRC-M10783), and Bifidobacterium bifidum strain T1 (IBRC-M10771) (2 × 109 CFU/g each) plus 800 mg inulin (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were taken at baseline and after the 12-week intervention to determine related variables. Compared with the placebo, synbiotic supplementation resulted in a significant reduction in serum insulin concentrations (- 2.8 ± 4.1 vs. + 1.8 ± 6.4 μIU/mL, P = 0.002) and homeostasis model of assessment-insulin resistance (- 0.7 ± 1.0 vs. + 0.4 ± 1.5, P = 0.002), and a significant elevation in the quantitative insulin sensitivity check index (+ 0.01 ± 0.01 vs. - 0.01 ± 0.03, P < 0.001). In addition, significant decreases in serum triglycerides (- 16.2 ± 31.4 vs. + 5.8 ± 23.1 mg/dL, P = 0.003), VLDL-cholesterol concentrations (- 3.3 ± 6.3 vs. + 1.1 ± 4.6 mg/dL, P = 0.003), and AIP (- 0.05 ± 0.08 vs. - 0.003 ± 0.10 mg/dL, P = 0.03) were seen following the supplementation of synbiotic compared with the placebo. Overall, we found that synbiotic supplementation to women with PCOS for 12 weeks had beneficial effects on markers of insulin resistance, triglycerides, VLDL-cholesterol concentrations, and AIP, but did not influence other lipid profiles. Trial registration: www.irct.ir: IRCT201604015623N71.

Authors+Show Affiliations

Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.Department of Gynecology and Obstetrics, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.Anatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, Iran.Science Faculty, Islamic Azad University, Central Branch, Tehran, Iran.Anatomical Sciences Research Center, Kashan University of Medical Sciences, Kashan, Iran.Research Center for Biochemistry and Nutrition in Metabolic Diseases, Kashan University of Medical Sciences, Kashan, Iran. asemi_r@yahoo.com.

Pub Type(s)

Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

29532416

Citation

Samimi, Mansooreh, et al. "The Effects of Synbiotic Supplementation On Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial." Probiotics and Antimicrobial Proteins, vol. 11, no. 4, 2019, pp. 1355-1361.
Samimi M, Dadkhah A, Haddad Kashani H, et al. The Effects of Synbiotic Supplementation on Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. Probiotics Antimicrob Proteins. 2019;11(4):1355-1361.
Samimi, M., Dadkhah, A., Haddad Kashani, H., Tajabadi-Ebrahimi, M., Seyed Hosseini, E., & Asemi, Z. (2019). The Effects of Synbiotic Supplementation on Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. Probiotics and Antimicrobial Proteins, 11(4), 1355-1361. https://doi.org/10.1007/s12602-018-9405-z
Samimi M, et al. The Effects of Synbiotic Supplementation On Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. Probiotics Antimicrob Proteins. 2019;11(4):1355-1361. PubMed PMID: 29532416.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Effects of Synbiotic Supplementation on Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. AU - Samimi,Mansooreh, AU - Dadkhah,Adeleh, AU - Haddad Kashani,Hamed, AU - Tajabadi-Ebrahimi,Maryam, AU - Seyed Hosseini,Elahe, AU - Asemi,Zatollah, PY - 2018/3/14/pubmed PY - 2020/7/3/medline PY - 2018/3/14/entrez KW - Glycemic control KW - Lipid profiles KW - Polycystic ovary syndrome KW - Probiotic bacteria KW - Synbiotic supplementation SP - 1355 EP - 1361 JF - Probiotics and antimicrobial proteins JO - Probiotics Antimicrob Proteins VL - 11 IS - 4 N2 - Data on the effects of synbiotic supplementation on glycemic control, lipid profiles, and atherogenic index of plasma (AIP) of women with polycystic ovary syndrome (PCOS) are limited. The purpose of this study was to assess the effects of synbiotic supplementation on glycemic control and lipid profiles in women with PCOS. A prospective, randomized, double-blind, placebo-controlled trial was done at the Naghavi Hospital affiliated to Kashan University of Medical Sciences, Kashan, Iran, between April 2017 and June 2017. Sixty women with PCOS were randomized to intake synbiotic capsule containing Lactobacillus acidophilus strain T16 (IBRC-M10785), Lactobacillus casei strain T2 (IBRC-M10783), and Bifidobacterium bifidum strain T1 (IBRC-M10771) (2 × 109 CFU/g each) plus 800 mg inulin (n = 30) or placebo (n = 30) for 12 weeks. Fasting blood samples were taken at baseline and after the 12-week intervention to determine related variables. Compared with the placebo, synbiotic supplementation resulted in a significant reduction in serum insulin concentrations (- 2.8 ± 4.1 vs. + 1.8 ± 6.4 μIU/mL, P = 0.002) and homeostasis model of assessment-insulin resistance (- 0.7 ± 1.0 vs. + 0.4 ± 1.5, P = 0.002), and a significant elevation in the quantitative insulin sensitivity check index (+ 0.01 ± 0.01 vs. - 0.01 ± 0.03, P < 0.001). In addition, significant decreases in serum triglycerides (- 16.2 ± 31.4 vs. + 5.8 ± 23.1 mg/dL, P = 0.003), VLDL-cholesterol concentrations (- 3.3 ± 6.3 vs. + 1.1 ± 4.6 mg/dL, P = 0.003), and AIP (- 0.05 ± 0.08 vs. - 0.003 ± 0.10 mg/dL, P = 0.03) were seen following the supplementation of synbiotic compared with the placebo. Overall, we found that synbiotic supplementation to women with PCOS for 12 weeks had beneficial effects on markers of insulin resistance, triglycerides, VLDL-cholesterol concentrations, and AIP, but did not influence other lipid profiles. Trial registration: www.irct.ir: IRCT201604015623N71. SN - 1867-1314 UR - https://www.unboundmedicine.com/medline/citation/29532416/The_Effects_of_Synbiotic_Supplementation_on_Metabolic_Status_in_Women_With_Polycystic_Ovary_Syndrome:_a_Randomized_Double_Blind_Clinical_Trial_ L2 - https://dx.doi.org/10.1007/s12602-018-9405-z DB - PRIME DP - Unbound Medicine ER -